• Blog-01april2014
  • WorldTBDAY2014
  • Blog-March14
  • Blog-08
  • Blog-001
  • Blog-07

Innovative financing

Developing sustainable sources of additional funds.    

arrow-red

read more

Market impact

Using secure funding to create incentives for producers.

arrow-red

read more

Healthier people

thank you members

  

 

  

RESULTS

map home-en

  

 

  

Print

UNITAID-funded TB projects

Pushing for scale-up of MDR-TB

UNITAID, together with its partners, is working to increase the number of patients that have access to MDR-TB treatment, accelerate scale-up, and prevent treatment interruption. It is working to reduce drug delivery times from three to six months down to three weeks. UNITAID is also encouraging more producers to enter the market, helping improve quality and reduce prices by up to 25% by 2011.

read more...

 

Rolling out a revolutionary rapid MDR-TB diagnostic

Diagnosing MDR-TB is very difficult, especially in resource-poor settings, where access to laboratories with sophisticated equipment can be limited. A new diagnostic test is now available which cuts the time it takes to diagnose MDR-TB from up to three months down to only two days. UNITAID has committed to funding these tests until 2011, with the aim of facilitating the response to 15% of the global MDR-TB burden, representing a three-fold increase over the current 5% of MDR-TB cases being diagnosed.

read more...

2010 update - Strengthening tuberculosis laboratories in Ethiopia what has been accomplished


Expanding access to tuberculosis treatment for children

UNITAID, through it partners, aims to provide more than 750,000 TB treatments to children under the age of 15 by 2011. It is also working to ensure the development and supply of new child-friendly TB formulations for children under four in at least 58 countries by 2011. By helping increase the number of manufacturers, UNITAID has additionally achieved price reductions for paediatric TB medicines of up to 18%. Further, UNITAIDs funding support to WHO has facilitated the prequalification of the first ever paediatric TB medicine.

read more... 

 

The first-line of defence against emerging resistance: securing first-line TB treatment

UNITAID, through its partner the Global Drug Facility (GDF) of the Stop TB Partnership, is ensuring there is steady availability of first-line drugs in countries by supporting the creation and implementation of a strategic rotating stockpile of first-line TB drugs. The UNITAID-GDF partnership is supporting the diagnosis and treatment of more than 866 000 patients by 2011. UNITAID is also working to stabilize and further reduce prices for first-line drugs through the predictable, long-term funding it provides.

read more...

About UNITAID (Short Animation)

 

Annual Report 2012

  • ar-en-2012

Implementers

  • partners-EN-1
  • partners-EN-2
  • partners-EN-3